瑞普生物股份有限公司 关于向控股子公司提供财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、本次财务资助对象为瑞普生物股份有限公司（以下简称"公司"）控股 子公司天津中瑞供应链管理有限公司（以下简称"中瑞供应链"），资助方式为 公司向中瑞供应链提供额度不超过人民币12,000万元的借款，额度范围内可循环 使用，财务资助额度的期限为自本次董事会审议批准之日起36个月。 2、本次财务资助事项已经公司第五届董事会第二十四次（临时）会议审议 通过，无需提交公司股东大会审议。 证券代码：300119 证券简称：瑞普生物 公告编号：2025-047 3、中瑞供应链其他股东未就本次财务资助事项提供同比例财务资助或担保。 一、财务资助事项概述 1、本次财务资助基本情况 为缓解控股子公司资金周转压力，满足其经营发展需要，公司拟在不影响自 身正常业务开展及资金使用的情况下，向中瑞供应链提供额度不超过人民币 12,000万元的借款，额度范围内可循环使用，财务资助额度的期限为自本次董事 会审议批准之日起36个月。中瑞供应链其他股东未就本次财务资助事项 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-048 瑞普生物股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2025年第三次临时股东大会 2、会议召集人：经公司第五届董事会第二十四次（临时）会议审议通过， 公司董事会决定召开2025年第三次临时股东大会。 3、会议召开的合法、合规性：本次股东大会的召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开时间： 现场会议召开时间：2025 年 6 月 30 日（星期一）14:30 网络投票时间为： 通过深圳证券交易所交易系统进行网络投票的时间为2025年6月30日09:15- 09:25、09:30-11:30和13:00-15:00； （1）在股权登记日 2025 年 6 月 23 日（星期一）下午收市时，在中国证券 登记结算有限责任公司深圳分公司登记在册的公司全体股东均有权出席股东大 会，并可以以书面形式委托代理人出席会议和参加表决，该股东代理人 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-045 瑞普生物股份有限公司 第五届监事会第二十次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十次（临时） 会议于 2025 年 6 月 13 日在公司会议室以现场方式召开。会议通知于 2025 年 6 月 11 日以书面及网络方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由周仲华先生主持。本次会议的召集、召开 和表决程序符合《公司法》《证券法》等法律法规和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于拟转让控股子公司股权暨募投项目转让的议案》 经审核，监事会认为：本次转让控股子公司湖南中岸生物药业有限公司 48.4213%股权及募投项目转让事项，符合公司当前的发展战略和业务规划，不存 在损害公司及全体股东利益的情形。因此，监事会同意本次股权转让暨募投项目 转让事项。 具体内容详见公司于 2025 年 6 月 13 日披露于深 ...

瑞普生物股份有限公司 第五届董事会第二十四次（临时）会议决议公告 证券代码：300119 证券简称：瑞普生物 公告编号：2025-044 2、审议通过了《关于向控股子公司提供财务资助的议案》 经审议，董事会同意公司在不影响自身正常业务开展及资金使用的情况下， 向天津中瑞供应链管理有限公司提供额度不超过人民币 12,000 万元的借款，额 度范围内可循环使用，财务资助额度的期限为自本次董事会审议批准之日起 36 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十四次（临 时）会议于 2025 年 6 月 13 日在公司会议室以现场结合通讯表决方式召开。会议 通知于 2025 年 6 月 11 日以书面及网络方式送达全体董事。公司应出席董事 9 人，实际出席董事 9 人，参与表决董事 9 人（其中董事李睿、杨鶄、独立董事郭 春林、才学鹏、李娅以通讯方式参会）。本次会议由董事长李守军先生主持，公 司高级管理人员列席了会议。本次会议的召集、召开和表决程序符合《公司法》 《证券法》等法律法规 ...

Core Viewpoint - The company plans to transfer 48.4213% equity stake in its subsidiary Zhong'an Bio to Jiangxi Twin Biological Technology Co., Ltd. for a transaction price of 115 million yuan, aiming to deepen strategic cooperation with aquaculture group clients and optimize asset and business structure [1] Group 1 - The transaction will result in the company holding a 20% equity stake in Zhong'an Bio after completion [1] - Zhong'an Bio will no longer be included in the company's consolidated financial statements following the transaction [1] - The transaction does not constitute a related party transaction or a major asset restructuring and is subject to approval by the company's shareholders' meeting [1]

Investment Rating - The report maintains a "Positive" investment rating for the pet hospital industry [13]. Core Insights - The pet hospital industry is experiencing growth driven by the pet economy, with a projected market size of 51.7 billion yuan by 2024, reflecting a CAGR of 21% from 2016 to 2024. The industry is characterized by a fragmented market with many small players, but leading companies are advancing in chain operations and professional transformation to enhance profitability [4][9][21]. - The report emphasizes the need for standardization and replicability in personnel and management to achieve economies of scale, alongside the establishment of a specialized integrated diagnosis and treatment system focusing on tiered diagnosis and specialty construction to optimize resource allocation and improve profit margins [4][10][20]. Summary by Sections Market Overview - The pet hospital market is expanding due to strong growth in the pet economy and the essential nature of pet care, with the market expected to reach 51.7 billion yuan in 2024. The market is currently fragmented, with leading companies accelerating their chain operations amidst a backdrop of high costs and low efficiency [9][21]. Industry Structure - The industry exhibits a "large market, many players, small shares" characteristic, with a low concentration level. As of 2024, there are 34,426 registered animal diagnosis institutions, but the top players hold only a small market share, indicating significant room for growth and consolidation [30][39]. Chain Operations and Professionalization - Chain operations are essential for growth, but rapid expansion can lead to high costs and low efficiency. The report suggests that successful chain hospitals must focus on standardizing operations and enhancing management practices to avoid pitfalls associated with rapid scaling [10][62]. - The establishment of a tiered diagnosis system and specialty services is crucial for optimizing medical resources and increasing profitability. This approach aligns with changing pet demographics and consumer expectations [10][34]. Company Spotlight: Ruipai Pet Hospital - Ruipai Pet Hospital, a leading chain in the industry, has over 600 locations across more than 70 cities, with an average annual revenue of over 3 million yuan per store. The company is expected to continue enhancing its chain rate and profitability through innovative management and specialized services [11][21].

Core Viewpoint - Reap Bio has announced that its product Miaopujing is set to be launched soon, following the recent launch of its other product Chaobixin in May this year [1] Company Summary - Reap Bio has successfully launched Chaobixin in May 2023 [1] - The upcoming launch of Miaopujing indicates the company's ongoing product development and market expansion efforts [1]

Market Performance - As of June 6, the Tianjin Free Trade Zone concept index rose by 2.60%, ranking second among concept sectors, with seven stocks increasing in value [1] - Notable gainers included HNA Technology, Bohai Chemical, and Haitai Development, which hit the daily limit, while HNA Technology, Tianjin Pulin, and Youfa Group saw increases of 9.03%, 2.68%, and 1.56% respectively [1] Sector Comparison - The Tianjin Free Trade Zone concept was among the top-performing sectors, with a net inflow of 120 million yuan from main funds, indicating strong investor interest [2] - The leading stocks in terms of net fund inflow were HNA Technology, Bohai Chemical, and Jintou City Development, with net inflows of 90.06 million yuan, 86.73 million yuan, and 47.65 million yuan respectively [2] Fund Flow Analysis - The net inflow ratios for Haitai Development, Jintou City Development, and Bohai Chemical were 51.10%, 20.62%, and 14.08% respectively, indicating significant investor confidence in these stocks [3] - The detailed fund flow data showed that HNA Technology had a trading volume of 90.06 million yuan with a turnover rate of 9.89%, while Bohai Chemical had a turnover rate of 13.09% [3][4]

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

Investment Rating - The report maintains a positive outlook on the agricultural sector, specifically highlighting investment opportunities in the pig farming and pet food industries [3][4]. Core Insights - The report emphasizes the strong performance of the pet food sector during the "618" shopping festival, with leading brands showing significant sales growth. It also notes the potential for re-evaluation of pig prices due to changing market conditions [4][5]. - The agricultural index increased by 1.8%, contrasting with a 1.1% decline in the Shanghai and Shenzhen 300 index, indicating a favorable market environment for agricultural stocks [5]. Summary by Sections Agricultural Stock Market Performance - The agricultural index rose by 1.8%, while the Shanghai and Shenzhen 300 index fell by 1.1%. The top five gainers included ST Tianshan (13.6%), Juxing Agriculture (13.2%), and Xiwang Food (12.4%) [5][12]. - The report suggests focusing on the sales performance of pet food during the "618" shopping festival and the re-evaluation of pig prices, particularly for undervalued leading pig farming companies [4][5]. Pig Farming - Pig prices continue to show strong fluctuations, with a national average selling price of 14.42 CNY/kg as of June 2, reflecting a week-on-week increase of 0.8%. The report indicates that the overall industry remains profitable, with a profit of 125.3 CNY per head for large-scale farms [4][5]. - The report highlights the expectation of a re-evaluation of pig prices in the second half of the year, driven by strong market realities and declining breeding costs [4][5]. Pet Food - The "618" shopping festival saw explosive sales in the pet food sector, with major brands performing exceptionally well. The festival's duration was extended, leading to increased sales [4][14]. - Key brands such as Guai Bao Pet and Zhongchong Co. showed significant improvements in their rankings on e-commerce platforms, indicating a strong market presence [21][23][28]. Animal Health - The report notes that the re-evaluation of pig prices may drive demand for animal health products, particularly vaccines. The first quarter of 2025 saw a 23.02% year-on-year increase in vaccine approvals [4][5]. - Companies focusing on pet health products are expected to benefit from the growing demand in the market [4][5].